atenolol has been researched along with Diabetic Glomerulosclerosis in 21 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria." | 7.68 | Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 6.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "The aim of the study was to evaluate the efficacy of enalapril and atenolol in decreasing the severity of proteinuria in hypertensive patients suffering from insulin-dependent diabetes mellitus." | 5.07 | Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. ( Andriani, A; Bonfantino, MV; De Cesaris, R; Filitti, V; Ranieri, G, 1993) |
| "Given a similar level of arterial pressure control, both lisinopril and diltiazem slow progression of diabetic renal disease and reduce albuminuria to a greater extent than does the combination of a loop diuretic and beta-adrenoreceptor antagonist." | 5.07 | Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. ( Bakris, GL; Sadler, R; Slataper, R; Vicknair, N, 1993) |
| "Atenolol, a first-generation β-blocker, effectively reduces blood pressure, although its use in metabolic syndrome remains controversial." | 3.77 | Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Muñoz, MC; Toblli, JE, 2011) |
| "Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria." | 3.68 | Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 2.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect." | 2.68 | Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997) |
| "The progression of diabetic nephropathy can be positively influenced by maintaining a low blood pressure level." | 2.67 | Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. ( Berden, JH; de Nobel, E; Elving, LD; van Lier, HJ; Wetzels, JF, 1994) |
| "Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function." | 2.67 | Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 12 (57.14) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toblli, JE | 1 |
| Cao, G | 1 |
| Giani, JF | 1 |
| Muñoz, MC | 1 |
| Angerosa, M | 1 |
| Dominici, FP | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Penmetsa, S | 1 |
| Simmons, M | 1 |
| Daugird, A | 1 |
| Carr, AA | 1 |
| Kowey, PR | 1 |
| Devereux, RB | 1 |
| Brenner, BM | 1 |
| Dahlöf, B | 1 |
| Ibsen, H | 1 |
| Lindholm, LH | 1 |
| Lyle, PA | 1 |
| Snapinn, SM | 1 |
| Zhang, Z | 1 |
| Edelman, JM | 1 |
| Shahinfar, S | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 1 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| De Cesaris, R | 1 |
| Ranieri, G | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Hardy, KJ | 1 |
| Elving, LD | 1 |
| Wetzels, JF | 1 |
| van Lier, HJ | 1 |
| de Nobel, E | 1 |
| Berden, JH | 1 |
| Nielsen, FS | 3 |
| Rossing, P | 3 |
| Gall, MA | 3 |
| Skøtt, P | 2 |
| Smidt, UM | 3 |
| Parving, HH | 3 |
| Slataper, R | 1 |
| Vicknair, N | 2 |
| Sadler, R | 2 |
| Bakris, GL | 2 |
| Schnack, C | 1 |
| Hoffmann, W | 1 |
| Hopmeier, P | 1 |
| Schernthaner, G | 1 |
| Mangrum, A | 1 |
| Copley, JB | 1 |
| Chen, JW | 1 |
| Sato, A | 1 |
| Bory, M | 1 |
| Faller, J | 1 |
| Hess, B | 1 |
| Stornello, M | 2 |
| Valvo, EV | 2 |
| Scapellato, L | 2 |
| Tindall, H | 2 |
| Urquhart, S | 1 |
| Stickland, M | 1 |
| Davies, JA | 2 |
| Hopper, AH | 1 |
2 reviews available for atenolol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Clinical inquiries. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diabetic N | 2005 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
12 trials available for atenolol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients.
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; Diabetic Neph | 1993 |
Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.
Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephrop | 1994 |
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Albuminuria; Apolipoproteins; Apoprotein(a); Atenolol; Blood Pressure; Circadian Rhythm; Diabetes Me | 1994 |
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
Topics: Albuminuria; Antihypertensive Agents; Atenolol; Diabetic Nephropathies; Diltiazem; Dipeptides; Furos | 1993 |
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 1996 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; | 1997 |
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Ateno | 1997 |
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Diabetes Mellitus | 1997 |
Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
Topics: Adult; Aged; Albuminuria; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1992 |
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Chronic Disease; Diabetic Nephropathies; Diabetic Retinopa | 1991 |
7 other studies available for atenolol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atenolol; Benzopyrans; Blood Pressure; Diabetes Mel | 2011 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Antihypertensives retarding progression of diabetic nephropathy.
Topics: Atenolol; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans | 1995 |
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2002 |
Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients.
Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephro | 1991 |
The course of incipient diabetic nephropathy.
Topics: Adult; Albuminuria; Atenolol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Middle Aged | 1986 |